Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

67%(2 trials)

Phase Distribution

Ph phase_3

33%

Ph phase_4

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 3Large-scale testing

1(33.3%)

Phase 4Post-market surveillance

2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 31 (33.3%)

Phase 42 (66.7%)

Trials by Status

completed3100%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_4

Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand

NCT02408926

completedphase_4

Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination

NCT01357720

completedphase_3

Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B

NCT01362517

Clinical Trials (3)

Showing 3 of 3 trials

NCT02408926Phase 4

Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand

Completed

NCT01357720Phase 4

Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination

Completed

NCT01362517Phase 3

Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B

Completed

All 3 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 3